MANNKIND CORP Operating Lease Right-of-Use Assets
MANNKIND CORP (MNKD) had Operating Lease Right-of-Use Assets of $10.85 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $10.85M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $11.29M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $11.82M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $11.29M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $10.85M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.29M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $11.82M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $11.29M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $11.79M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $12.56M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.64M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.07M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $4.39M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $4.68M 10-K · filed 2025-02-26 |
| 2023-09-30 | $5.01M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.33M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $5.65M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $6.71M 10-K · filed 2024-02-27 |
| 2022-09-30 | $7.05M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $2.28M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |